Main
results of Intergroup adjuvant premenopausal study
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
What
came out of it was that the five year disease-free survival was
statistically better for the women who took the CAF, Zoladex, tamoxifen
than for the women who took the CAF followed by the Zoladex. There
was a borderline impact of CAF-Zoladex as compared to CAF –
no survival differences, not surprisingly, 85% survival across all
the arms at the time that we looked at. We then did some unplanned,
retrospective, sub-set analyses and what’s come out of those,
in a very preliminary fashion, is that in the younger women, which
we arbitrarily defined as women under the age of 40, they actually
seemed to do better with the castration part of the trial. And,
perhaps that’s not surprising because those were the women
who’d be least likely to be made postmenopausal by the chemotherapy.
We also had looked at serial hormone levels during the course of
the trial, and we had reasonable information about a random estradiol
level at the end of chemotherapy in about 1,000 women. So, we also
tried to use that as a marker for menstrual function at the end
of chemotherapy, and there’s a suggestion from this retrospective
analysis that the women who had premenopausal estrogen levels at
the end of chemotherapy were those who were destined to have some
benefit with the Zoladex.
Combined
endocrine therapy for breast cancer - New life for an old idea? Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute 92(11):859-860, 2000 Jun 7. No
abstract
